1009107-27-0

Basic information

• Product Name: Daclatasvir Impurity 4
• Synonyms: Daclatasvir Impurity 4;Daclatasvir Impurity (RSSR-isomer);Daclatasvir Impurity A;N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1R)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic Acid C,C'-Dimethyl Ester
• CAS NO: 1009107-27-0
• Molecular Formula: C40H50N8O6
• Molecular Weight: 738.875
• EINECS: -0
• Mol File: 1009107-27-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 1071.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.249±0.06 g/cm3(Predicted)
• PKA: 10.92±0.46(Predicted)
• CAS DataBase Reference: Daclatasvir Impurity 4(CAS DataBase Reference)
• NIST Chemistry Reference: Daclatasvir Impurity 4(1009107-27-0)
• EPA Substance Registry System: Daclatasvir Impurity 4(1009107-27-0)

Safety Data

• Hazardous Substances Data: 1009107-27-0(Hazardous Substances Data)

Usage

Description

Daclatasvir Impurity 4 is an isomer of Daclatasvir (D101500), a compound that inhibits the HCV protein NS5A. It is a pharmaceutical impurity that may be present during the synthesis or formulation of Daclatasvir, which is a drug candidate for the treatment of hepatitis C (HCV).

Uses

Used in Pharmaceutical Industry:
Daclatasvir Impurity 4 is used as a drug candidate for the treatment of hepatitis C (HCV) due to its inhibitory effect on the HCV protein NS5A. It plays a crucial role in the development and formulation of Daclatasvir-based medications, ensuring the safety and efficacy of the final drug product.

Upstream product

• 1009119-83-8 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate hydrochloride 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 1009119-83-8 1H-imidazole,5,5'-[1,1'-biphenyl]-4,4'-bis[2-(2S)-2-pyrrolidine-2yl hydrochloride] 
• 1007882-27-0 2-[(2S)-pyrrolidin-2-yl]-5-[4-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)phenyl]-1H-imidazole 
• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1312335-96-8 C₄₀H₄₈Br₂N₈O₆ 

Relevant articles and documents

Micro-electro-flow reactor (μ-EFR) system for ultra-fast arene synthesis and manufacture of daclatasvir

The World Health Organization (WHO) has listed daclatasvir (DCV), symmetrical arene, as one of the essential medicines for human health. DCV manufacturing is usually carried out in a non-continuous or "batch" approach over multiple locations and is severely limited by long production times (3-10 days), resulting in non-affordability (highly expensive) and disruption of the potential chain supply. Here, we report the total process system including the development of a novel electro-flow reactor containing patterned electrodeposited Ni or Pt nanoparticles over a copper electrode for a C-C coupling reaction in a co-reductant/oxidant-free, ultra-fast process for symmetrical substituted/unsubstituted biphenyl synthesis. This method was further extended to a new generation commercial batch synthetic route for continuous flow ultra-fast daclatasvir synthesis in 33.2 min. We envisage that this micro-electro-flow reactor (μ-EFR) system platform will substantially enable advances in continuous-μ-flow fine chemical manufacturing, multistep reaction sequences, reaction devising equipment, and real-time extraction.

Synthetic method of daclatasvir

The invention discloses a synthetic method of daclatasvir. The method adopts bis(2-bromoacetyl) biphenyl and t-butyloxycarboryl-L-proline as initial raw materials, the initial raw materials are separately synthesized into a midbody N-4, N-3, N-2 and N-1 i

PROCESS FOR THE PREPARATION OF DACLATASVIR

The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates. Formula (I)